TB Alliance and BioFocus Sign Compound Management Agreement
News Jan 11, 2010
BioFocus announced that it has signed a three year compound management agreement with the Global Alliance for TB Drug Development (TB Alliance).
Under this agreement BioFocus will manage TB Alliance’s chemical library collection. These services will be provided by BioFocus’ compound management facility in South San Francisco, USA.
“We are pleased to welcome TB Alliance as a new client to our compound management services, joining other prestigious names such as the National Institutes of Health,” said Scott Snyder, BioFocus’ Senior Director, Compound Management. “This collaboration leverages our full suite of compound management services and further expands our client base of not-for-profit discovery organizations to a global level.”
Worms Exhibit Fear and Respond to Anti-anxiety MedsNews
A team of investigators has uncovered new clues about the mechanisms of fear and anxiety through an unlikely creature: the tiny nematode worm.READ MORE
Stem Cells in Menstrual Blood Could Help Diagnose EndometriosisNews
The Feinstein Institute for Medical Research scientists announced an experimental, rapid and non-invasive way to diagnose endometriosis, which may lead to earlier and more effective treatments for this disorder that affects approximately 176 million women globally.READ MORE
SMi’s 5th Annual Molecular Diagnostics Conference 2018 Agenda ReleasedNews
SMi proudly presents its 5th annual conference on Molecular Diagnostics, taking place at the Holiday Inn Kensington Forum, London, UK on 9th and 10th July 2018, with a half-day post-conference workshops on 11th July 2018.READ MORE